메뉴 건너뛰기




Volumn 3, Issue , 2011, Pages 1-7

Bones, breasts, and bisphosphonates: Rationale for the use of zoledronic acid in advanced and early breast cancer

Author keywords

Adjuvant therapy; Anticancer; Bone metastasis; Skeletal; Zoledronic acid

Indexed keywords

CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

EID: 79952645527     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S16774     Document Type: Review
Times cited : (3)

References (66)
  • 2
    • 79951575730 scopus 로고    scopus 로고
    • American Cancer Society, Atlanta, GA: American Cancer Society 2010
    • American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
    • (2010) Cancer Facts and Figures
  • 3
    • 0030749321 scopus 로고    scopus 로고
    • Skeletal complications of malignancy
    • Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-1594.
    • (1997) Cancer , vol.80 , Issue.8 SUPPL. , pp. 1588-1594
    • Coleman, R.E.1
  • 4
    • 35048875471 scopus 로고    scopus 로고
    • Pathologic fractures correlate with reduced survival in patients with malignant bone disease
    • Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867.
    • (2007) Cancer , vol.110 , Issue.8 , pp. 1860-1867
    • Saad, F.1    Lipton, A.2    Cook, R.3    Chen, Y.M.4    Smith, M.5    Coleman, R.6
  • 5
    • 0037241535 scopus 로고    scopus 로고
    • In vitro and in vivo antitumor effects of bisphosphonates
    • Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem. 2003;10(2): 173-180.
    • (2003) Curr Med Chem , vol.10 , Issue.2 , pp. 173-180
    • Clezardin, P.1    Fournier, P.2    Boissier, S.3    Peyruchaud, O.4
  • 6
    • 49949115926 scopus 로고    scopus 로고
    • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy
    • Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy. Lancet Oncol. 2008;9(9):840-849.
    • (2008) Lancet Oncol , vol.9 , Issue.9 , pp. 840-849
    • Gnant, M.1    Mlineritsch, B.2    Luschin-Ebengreuth, G.3
  • 7
    • 34250326616 scopus 로고    scopus 로고
    • Meta-analysis of clodronate and breast cancer survival
    • Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96(12):1796-1801.
    • (2007) Br J Cancer , vol.96 , Issue.12 , pp. 1796-1801
    • Ha, T.C.1    Li, H.2
  • 8
    • 54249151531 scopus 로고    scopus 로고
    • Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
    • Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26(29): 4739-4745.
    • (2008) J Clin Oncol , vol.26 , Issue.29 , pp. 4739-4745
    • Hershman, D.L.1    McMahon, D.J.2    Crew, K.D.3
  • 10
    • 6844252283 scopus 로고    scopus 로고
    • Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group
    • Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2): 593-602.
    • (1998) J Clin Oncol , vol.16 , Issue.2 , pp. 593-602
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 11
    • 0035312469 scopus 로고    scopus 로고
    • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
    • Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191-1200.
    • (2001) Cancer , vol.91 , Issue.7 , pp. 1191-1200
    • Berenson, J.R.1    Rosen, L.S.2    Howell, A.3
  • 12
    • 17144447171 scopus 로고    scopus 로고
    • Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    • Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
    • (2003) Ann Oncol , vol.14 , Issue.9 , pp. 1399-1405
    • Body, J.J.1    Diel, I.J.2    Lichinitser, M.R.3
  • 13
    • 1942501727 scopus 로고    scopus 로고
    • Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies
    • Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
    • (2004) Br J Cancer , vol.90 , Issue.6 , pp. 1133-1137
    • Body, J.J.1    Diel, I.J.2    Lichinitzer, M.3
  • 14
    • 0031810467 scopus 로고    scopus 로고
    • Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Danish-Swedish co-operative study group
    • Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol. 1998;101(2):280-286.
    • (1998) Br J Haematol , vol.101 , Issue.2 , pp. 280-286
    • Brincker, H.1    Westin, J.2    Abildgaard, N.3
  • 15
    • 0042331464 scopus 로고    scopus 로고
    • A double-blind, placebocontrolled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
    • Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebocontrolled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95(17): 1300-1311.
    • (2003) J Natl Cancer Inst , vol.95 , Issue.17 , pp. 1300-1311
    • Dearnaley, D.P.1    Sydes, M.R.2    Mason, M.D.3
  • 16
    • 77957332677 scopus 로고    scopus 로고
    • Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial
    • Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11(10): 973-982.
    • (2010) Lancet Oncol , vol.11 , Issue.10 , pp. 973-982
    • Gimsing, P.1    Carlson, K.2    Turesson, I.3
  • 17
    • 20644449488 scopus 로고    scopus 로고
    • Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
    • Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
    • (2005) J Clin Oncol , vol.23 , Issue.15 , pp. 3314-3321
    • Kohno, N.1    Aogi, K.2    Minami, H.3
  • 19
    • 0026646339 scopus 로고
    • Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group
    • Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340(8827): 1049-1052.
    • (1992) Lancet , vol.340 , Issue.8827 , pp. 1049-1052
    • Lahtinen, R.1    Laakso, M.2    Palva, I.3    Virkkunen, P.4    Elomaa, I.5
  • 20
    • 0034162528 scopus 로고    scopus 로고
    • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
    • Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5):1082-1090.
    • (2000) Cancer , vol.88 , Issue.5 , pp. 1082-1090
    • Lipton, A.1    Theriault, R.L.2    Hortobagyi, G.N.3
  • 21
    • 0031911183 scopus 로고    scopus 로고
    • A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults
    • McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100(2):317-325.
    • (1998) Br J Haematol , vol.100 , Issue.2 , pp. 317-325
    • McCloskey, E.V.1    Maclennan, I.C.2    Drayson, M.T.3    Chapman, C.4    Dunn, J.5    Kanis, J.A.6
  • 22
    • 0036570071 scopus 로고    scopus 로고
    • Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
    • Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20(9):2353-2359.
    • (2002) J Clin Oncol , vol.20 , Issue.9 , pp. 2353-2359
    • Menssen, H.D.1    Sakalova, A.2    Fontana, A.3
  • 23
    • 0027531814 scopus 로고
    • Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
    • Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65.
    • (1993) J Clin Oncol , vol.11 , Issue.1 , pp. 59-65
    • Paterson, A.H.1    Powles, T.J.2    Kanis, J.A.3    McCloskey, E.4    Hanson, J.5    Ashley, S.6
  • 24
    • 0035463593 scopus 로고    scopus 로고
    • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
    • Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
    • (2001) Cancer J , vol.7 , Issue.5 , pp. 377-387
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 25
    • 10744233021 scopus 로고    scopus 로고
    • Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
    • Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
    • (2003) Cancer , vol.98 , Issue.8 , pp. 1735-1744
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 26
    • 0042914647 scopus 로고    scopus 로고
    • Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    • Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
    • (2003) J Clin Oncol , vol.21 , Issue.16 , pp. 3150-3157
    • Rosen, L.S.1    Gordon, D.2    Tchekmedyian, S.3
  • 27
    • 0037009822 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , Issue.19 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 28
    • 0642337996 scopus 로고    scopus 로고
    • Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
    • Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-4284.
    • (2003) J Clin Oncol , vol.21 , Issue.23 , pp. 4277-4284
    • Small, E.J.1    Smith, M.R.2    Seaman, J.J.3    Petrone, S.4    Kowalski, M.O.5
  • 29
    • 17444435152 scopus 로고    scopus 로고
    • Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases
    • Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88(7):701-707.
    • (2001) Bull Cancer , vol.88 , Issue.7 , pp. 701-707
    • Tubiana-Hulin, M.1    Beuzeboc, P.2    Mauriac, L.3
  • 30
    • 79952648900 scopus 로고    scopus 로고
    • Zometa [prescribing information], NJ: Novartis Pharmaceuticals Corporation
    • Zometa [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
    • (2009) East Hanover
  • 31
    • 79952674051 scopus 로고    scopus 로고
    • Aredia [prescribing information], NJ: Novartis Pharmaceuticals Corporation
    • Aredia [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
    • (2008) East Hanover
  • 32
    • 77953225071 scopus 로고    scopus 로고
    • Xgeva [prescribing information], CA: Amgen Inc
    • Xgeva [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2010.
    • (2010) Thousand Oaks
  • 33
    • 79952684496 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology
    • Published 2010. Updated December 6, 2010. Accessed January 5, 2011
    • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V.2.2011. www.nccn.org. Published 2010. Updated December 6, 2010. Accessed January 5, 2011.
    • (2011) Breast Cancer , vol.2
  • 34
    • 28844439011 scopus 로고    scopus 로고
    • Anti-tumour activity of zoledronic acid
    • Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev. 2005;31(Suppl 3):1-8.
    • (2005) Cancer Treat Rev , vol.31 , Issue.SUPPL. 3 , pp. 1-8
    • Clezardin, P.1
  • 35
    • 72849140888 scopus 로고    scopus 로고
    • Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials
    • Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets. 2009;9(7): 824-833.
    • (2009) Curr Cancer Drug Targets , vol.9 , Issue.7 , pp. 824-833
    • Gnant, M.1
  • 36
    • 52049103847 scopus 로고    scopus 로고
    • The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
    • Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14(9):2519-2526.
    • (2008) Clin Cancer Res , vol.14 , Issue.9 , pp. 2519-2526
    • Meads, M.B.1    Hazlehurst, L.A.2    Dalton, W.S.3
  • 37
    • 19944432878 scopus 로고    scopus 로고
    • Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    • Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59-69.
    • (2005) J Natl Cancer Inst , vol.97 , Issue.1 , pp. 59-69
    • Brown, J.E.1    Cook, R.J.2    Major, P.3
  • 38
    • 24644479228 scopus 로고    scopus 로고
    • Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    • Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925-4935.
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 4925-4935
    • Coleman, R.E.1    Major, P.2    Lipton, A.3
  • 39
    • 35548960086 scopus 로고    scopus 로고
    • Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity
    • Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007;12(9): 1035-1043.
    • (2007) Oncologist , vol.12 , Issue.9 , pp. 1035-1043
    • Lipton, A.1    Cook, R.J.2    Major, P.3    Smith, M.R.4    Coleman, R.E.5
  • 40
    • 47149118386 scopus 로고    scopus 로고
    • Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
    • Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113(1):193-201.
    • (2008) Cancer , vol.113 , Issue.1 , pp. 193-201
    • Lipton, A.1    Cook, R.2    Saad, F.3
  • 41
    • 77955457605 scopus 로고    scopus 로고
    • A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
    • Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010; 15(4):382-389.
    • (2010) Int J Clin Oncol , vol.15 , Issue.4 , pp. 382-389
    • Zaghloul, M.S.1    Boutrus, R.2    El-Hossieny, H.3    Kader, Y.A.4    El-Attar, I.5    Nazmy, M.6
  • 42
    • 36248938315 scopus 로고    scopus 로고
    • Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
    • Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227-230.
    • (2007) Med Oncol , vol.24 , Issue.2 , pp. 227-230
    • Aviles, A.1    Nambo, M.J.2    Neri, N.3    Castaneda, C.4    Cleto, S.5    Huerta-Guzman, J.6
  • 43
    • 78650174738 scopus 로고    scopus 로고
    • National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial
    • Morgan GJ, Davies FE, Gregory WM, et al; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
    • (2010) Lancet , vol.376 , Issue.9757 , pp. 1989-1999
    • Morgan, G.J.1    Davies, F.E.2    Gregory, W.M.3
  • 45
    • 0034037097 scopus 로고    scopus 로고
    • Osteoporosis due to cancer treatment: Pathogenesis and management
    • Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570-1593.
    • (2000) J Clin Oncol , vol.18 , Issue.7 , pp. 1570-1593
    • Pfeilschifter, J.1    Diel, I.J.2
  • 46
    • 33947539707 scopus 로고    scopus 로고
    • Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
    • Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820-828.
    • (2007) J Clin Oncol , vol.25 , Issue.7 , pp. 820-828
    • Gnant, M.F.1    Mlineritsch, B.2    Luschin-Ebengreuth, G.3
  • 47
    • 41949094767 scopus 로고    scopus 로고
    • Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
    • Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051-1057.
    • (2008) J Clin Oncol , vol.26 , Issue.7 , pp. 1051-1057
    • Eastell, R.1    Adams, J.E.2    Coleman, R.E.3
  • 48
    • 60549097419 scopus 로고    scopus 로고
    • Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    • Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7):679-691.
    • (2009) N Engl J Med , vol.360 , Issue.7 , pp. 679-691
    • Gnant, M.1    Mlineritsch, B.2    Schippinger, W.3
  • 49
    • 84858230560 scopus 로고    scopus 로고
    • Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
    • Mature results from ABCSG-12, ASCO); June 4-8, 2010; Chicago, IL. Abstract 533
    • Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. Presented at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO); June 4-8, 2010; Chicago, IL. Abstract 533.
    • Presented At 46th Annual Meeting of the American Society of Clinical Oncology
    • Gnant, M.1    Mlineritsch, B.2    Stoeger, H.3
  • 50
    • 51649118688 scopus 로고    scopus 로고
    • Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo
    • Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14(14):4658-4666.
    • (2008) Clin Cancer Res , vol.14 , Issue.14 , pp. 4658-4666
    • Ottewell, P.D.1    Deux, B.2    Monkkonen, H.3
  • 51
    • 77952305169 scopus 로고    scopus 로고
    • Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial
    • Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-428.
    • (2010) Lancet Oncol , vol.11 , Issue.5 , pp. 421-428
    • Aft, R.1    Naughton, M.2    Trinkaus, K.3
  • 52
    • 79952649231 scopus 로고
    • ZOL on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results
    • Presented At 46th Annual Meeting of the American Society of Clinical Oncology; June 4-8 Chicago, IL. Abstract
    • Greenberg S, Park JW, Melisko ME, et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results. Presented at 46th Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, IL. Abstract 1002.
    • (1002) Effect of adjuvant zoledronic acid
    • Greenberg, S.1    Park, J.W.2    Melisko, M.E.3
  • 53
    • 77954572691 scopus 로고    scopus 로고
    • Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer
    • Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30(5):1807-1813.
    • (2010) Anticancer Res , vol.30 , Issue.5 , pp. 1807-1813
    • Rack, B.1    Juckstock, J.2    Genss, E.M.3
  • 54
    • 79952646544 scopus 로고    scopus 로고
    • Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients
    • San Antonio, TX. Abstract
    • Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2048.
    • (2048) Presented At 31st Annual San Antonio Breast Cancer Symposium
    • Solomayer, E.F.1    Gebauer, G.2    Hirnle, P.3
  • 55
    • 13944259758 scopus 로고    scopus 로고
    • The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
    • Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103(5):884-891.
    • (2005) Cancer , vol.103 , Issue.5 , pp. 884-891
    • Janni, W.1    Rack, B.2    Schindlbeck, C.3
  • 56
    • 34547743433 scopus 로고    scopus 로고
    • Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas
    • Schindlbeck C, Kampik T, Janni W, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res. 2005;7(6): R1174-R1185.
    • (2005) Breast Cancer Res , vol.7 , Issue.6
    • Schindlbeck, C.1    Kampik, T.2    Janni, W.3
  • 57
    • 61349156290 scopus 로고    scopus 로고
    • Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow
    • 20s. Abstract 559
    • Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol. 2008;26(Suppl):20s. Abstract 559.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL
    • Lin, A.Y.1    Park, J.W.2    Scott, J.3
  • 58
    • 77949541181 scopus 로고    scopus 로고
    • Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: Evidence of synergistic interaction
    • Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer. 2010;102(6):1010-1017.
    • (2010) Br J Cancer , vol.102 , Issue.6 , pp. 1010-1017
    • Neville-Webbe, H.L.1    Coleman, R.E.2    Holen, I.3
  • 59
    • 77954580167 scopus 로고    scopus 로고
    • Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
    • Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21(11):2188-2194.
    • (2010) Ann Oncol , vol.21 , Issue.11 , pp. 2188-2194
    • Eidtmann, H.1    de Boer, R.2    Bundred, N.3
  • 60
    • 78649241430 scopus 로고    scopus 로고
    • Postmenopausal women with early breast cancer receiving adjuvant letrozole
    • Zoledronic acid prevents aromatase inhibitor-associated bone loss in, E-ZO-FAST 36-month follow-up. Presented at, October 8-10, 2009; San Francisco, CA. Abstract 213
    • Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at 2009 ASCO Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA. Abstract 213.
    • (2009) ASCO Breast Cancer Symposium
    • Llombart, A.1    Frassoldati, A.2    Paija, O.3
  • 62
    • 67649804881 scopus 로고    scopus 로고
    • Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
    • Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77-85.
    • (2009) Clin Breast Cancer , vol.9 , Issue.2 , pp. 77-85
    • Brufsky, A.M.1    Bosserman, L.D.2    Caradonna, R.R.3
  • 66
    • 77950370156 scopus 로고    scopus 로고
    • The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer
    • Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102:1099-1105.
    • (2010) Br J Cancer , vol.102 , pp. 1099-1105
    • Coleman, R.E.1    Winter, M.C.2    Cameron, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.